Marshall Wace North America L.P. lifted its position in shares of Avanos Medical Inc (NYSE:AVNS) by 38.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 45,573 shares of the company’s stock after acquiring an additional 12,768 shares during the quarter. Marshall Wace North America L.P. owned approximately 0.10% of Avanos Medical worth $1,945,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in AVNS. Norges Bank bought a new position in Avanos Medical during the 4th quarter worth $33,253,000. Victory Capital Management Inc. increased its position in Avanos Medical by 31.3% in the 1st quarter. Victory Capital Management Inc. now owns 2,196,725 shares of the company’s stock valued at $93,756,000 after buying an additional 523,550 shares in the last quarter. Rice Hall James & Associates LLC bought a new stake in Avanos Medical in the 1st quarter valued at about $16,219,000. Champlain Investment Partners LLC increased its position in Avanos Medical by 14.5% in the 1st quarter. Champlain Investment Partners LLC now owns 2,401,987 shares of the company’s stock valued at $102,517,000 after buying an additional 304,015 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. increased its position in Avanos Medical by 416.2% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 346,095 shares of the company’s stock valued at $15,502,000 after buying an additional 279,054 shares in the last quarter. 93.42% of the stock is currently owned by institutional investors.
In related news, CEO Joseph Fralin Woody purchased 3,500 shares of the firm’s stock in a transaction that occurred on Thursday, May 30th. The stock was bought at an average cost of $39.95 per share, with a total value of $139,825.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 1.57% of the stock is owned by corporate insiders.
Avanos Medical (NYSE:AVNS) last released its quarterly earnings results on Tuesday, May 7th. The company reported $0.15 earnings per share for the quarter, missing the consensus estimate of $0.17 by ($0.02). The firm had revenue of $164.20 million during the quarter, compared to the consensus estimate of $163.72 million. Avanos Medical had a return on equity of 4.92% and a net margin of 2.58%. The company’s revenue for the quarter was up 5.0% compared to the same quarter last year. During the same period in the previous year, the company posted $0.76 EPS. On average, sell-side analysts forecast that Avanos Medical Inc will post 1.24 EPS for the current fiscal year.
A number of equities analysts have issued reports on AVNS shares. Zacks Investment Research downgraded GALP ENERGIA SG/ADR from a “hold” rating to a “sell” rating in a research note on Monday, May 6th. Morgan Stanley reiterated an “overweight” rating and set a GBX 2,280 ($29.79) price target on shares of Anglo American in a research note on Wednesday, May 8th. Finally, ValuEngine downgraded Zumiez from a “hold” rating to a “sell” rating in a research note on Tuesday, July 2nd. Three investment analysts have rated the stock with a sell rating and three have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $63.00.
Avanos Medical Profile
Avanos Medical, Inc operates as a medical technology company that focuses on delivering medical device solutions to improve patients' quality of life worldwide. It provides a portfolio of products focuses on respiratory and digestive health; pain management solutions; and minimally invasive interventional pain therapies, closed airway suction systems, and enteral feeding tubes.
Featured Article: What are retained earnings?
Receive News & Ratings for Avanos Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avanos Medical and related companies with MarketBeat.com's FREE daily email newsletter.